Avoro Capital Advisors LLC reported 25 positions worth $11.10B for the quarter ended Jun 30, 2026, up 25.7% on the prior quarter. It opened 1 new position, added to 12, trimmed 3 and exited 2. Its largest holding is UNITED THERAPEUTICS Corp at 13.6% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| CYTK Cytokinetics Inc | +1.67M | +50.0% | $141.98M | 3.84% |
| DFTX Definium Therapeutics, Inc. | +2.19M | +43.8% | $102.97M | 3.05% |
| UTHR UNITED THERAPEUTICS Corp | +147.8K | +5.6% | $80.07M | 13.56% |
| COAG Hemab Therapeutics Holdings, Inc. | +1.93M | – | $70.71M | 0.637% |
| ARWR Arrowhead Pharmaceuticals, Inc. | +655.6K | +6.1% | $53.43M | 8.34% |
| QURE uniQure N.V. | +768.2K | +12.9% | $35.38M | 2.79% |
| VRDN Viridian Therapeutics, Inc.\DE | +1.00M | +66.7% | $18.37M | 0.414% |
| AVTX Avalo Therapeutics, Inc. | +923.3K | +65.5% | $17.06M | 0.388% |
| TSHA Taysha Gene Therapies, Inc. | +2.19M | +10.1% | $14.91M | 1.47% |
| ASND Ascendis Pharma A/S | +48.6K | +1.0% | $12.97M | 12.28% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| ALKS Alkermes plc. | -1.20M | -100.0% | $42.43M | Exited |
| RVMD Revolution Medicines, Inc. | -47.4K | -2.0% | $8.89M | 3.88% |
| VERA Vera Therapeutics, Inc. | -165.0K | -2.8% | $7.08M | 2.21% |
| MNKD Mannkind Corp | -2.20M | -100.0% | $5.39M | Exited |
| LXEO Lexeo Therapeutics, Inc. | -385.8K | -20.6% | $1.80M | 0.062% |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| COAG Hemab Therapeutics Holdings, Inc. | +1.93M | $70.71M | 0.637% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | UTHR UNITED THERAPEUTICS Corp | Healthcare | 2.78M | $1.51B | 13.56% | +147.8K | +5.6% | Added | 6.51% |
| 2 | ASND Ascendis Pharma A/S | Healthcare | 5.11M | $1.36B | 12.28% | +48.6K | +1.0% | Added | 8.43% |
| 3 | KRYS Krystal Biotech, Inc. | Healthcare | 2.89M | $1.07B | 9.67% | 0 | 0.0% | Unchanged | 9.76% |
| 4 | MDGL Madrigal Pharmaceuticals, Inc. | Healthcare | 1.83M | $984.41M | 8.87% | +15.2K | +0.8% | Added | 6.29% |
| 5 | ARGX Argenx Se | Healthcare | 1.00M | $927.77M | 8.36% | 0 | 0.0% | Unchanged | 1.63% |
| 6 | ARWR Arrowhead Pharmaceuticals, Inc. | Healthcare | 11.36M | $925.59M | 8.34% | +655.6K | +6.1% | Added | 7.92% |
| 7 | KYMR Kymera Therapeutics, Inc. | Healthcare | 7.47M | $857.13M | 7.72% | 0 | 0.0% | Unchanged | 7.61% |
| 8 | RVMD Revolution Medicines, Inc. | Healthcare | 2.30M | $430.18M | 3.88% | -47.4K | -2.0% | Reduced | 1.07% |
| 9 | CYTK Cytokinetics Inc | Healthcare | 5.00M | $425.95M | 3.84% | +1.67M | +50.0% | Added | 3.6% |
| 10 | CELC Celcuity Inc. | Healthcare | 3.40M | $355.71M | 3.2% | +25.0K | +0.7% | Added | 6.2% |
| 11 | GPCR Structure Therapeutics Inc. | Healthcare | 6.56M | $351.84M | 3.17% | 0 | 0.0% | Unchanged | 3.01% |
| 12 | XENE Xenon Pharmaceuticals Inc. | Healthcare | 5.78M | $348.75M | 3.14% | 0 | 0.0% | Unchanged | 5.8% |
| 13 | DFTX Definium Therapeutics, Inc. | Healthcare | 7.19M | $338.17M | 3.05% | +2.19M | +43.8% | Added | 5.35% |
| 14 | QURE uniQure N.V. | Healthcare | 6.73M | $309.88M | 2.79% | +768.2K | +12.9% | Added | 9.7% |
| 15 | VERA Vera Therapeutics, Inc. | Healthcare | 5.72M | $245.61M | 2.21% | -165.0K | -2.8% | Reduced | 7.97% |
Tip. Select a row to see that position’s full history at Avoro Capital Advisors.
As of its Q2 2026 13F filing, Avoro Capital Advisors LLC’s five largest positions were UNITED THERAPEUTICS Corp (UTHR) at 13.6%, Ascendis Pharma A/S (ASND) at 12.3%, Krystal Biotech, Inc. (KRYS) at 9.7%, Madrigal Pharmaceuticals, Inc. (MDGL) at 8.9%, Argenx Se (ARGX) at 8.4% of the reported portfolio.
Avoro Capital Advisors LLC reported a 13F portfolio worth $11.10B across 25 positions for Q2 2026. That is up 25.7% from the previous quarter.
Its largest purchases by value were Cytokinetics Inc ($141.98M), Definium Therapeutics, Inc. ($102.97M), UNITED THERAPEUTICS Corp ($80.07M). It opened 1 new positions.
Its largest sales by value were Alkermes plc. ($42.43M), Revolution Medicines, Inc. ($8.89M), Vera Therapeutics, Inc. ($7.08M). It exited 2 positions entirely.
From the Form 13F-HR reports Avoro Capital Advisors LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.